-
1 Comment
Daewoong Co., Ltd is currently in a long term uptrend where the price is trading 5.8% above its 200 day moving average.
From a valuation standpoint, the stock is 88.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Daewoong Co., Ltd's total revenue sank by 2.1% to $345B since the same quarter in the previous year.
Its net income has increased by 514.8% to $57B since the same quarter in the previous year.
Finally, its free cash flow grew by 156.9% to $17B since the same quarter in the previous year.
Based on the above factors, Daewoong Co., Ltd gets an overall score of 4/5.
| ISIN | KR7003090008 |
|---|---|
| Exchange | KO |
| CurrencyCode | KRW |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Dividend Yield | 1.0% |
|---|---|
| Market Cap | 832B |
| PE Ratio | None |
| Target Price | 28000 |
| Beta | 1.53 |
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1945 and is headquartered in Seongnam, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 003090.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
